Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
Delayed Nasdaq  -  04:00 2022-11-29 pm EST
35.67 USD   +0.76%
11/29Transcript : Ultragenyx Pharmaceutical Inc. Presents at Piper Sandler 34th Annual Healthcare Conference, Nov-29-2022 10:00 AM
CI
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Days
:
Hours
:
Minutes
:
Seconds
Business Summary
Logo Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company, which is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The CompanyÔÇÖs therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The CompanyÔÇÖs four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company' clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.

Number of employees : 1 119 people.
Sales per Business
20202021Delta
Products for the Treatment of Serious Rare and Ultra-rare Genetic Diseases271.03100%351.41100% +29.66%
USD in Million
Sales per region
20202021Delta
North America237.6787.7%301.1185.7% +26.69%
Europe21.327.9%26.667.6% +25.06%
All Other12.054.4%23.646.7% +96.21%
USD in Million
Managers
Name Title Age Since
Emil Kakkis President, Chief Executive Officer & Director 60 2010
Dennis Huang Chief Technical Operations Officer & Senior VP 56 2016
Camille Bedrosian Chief Medical Officer & Executive Vice President 68 2018
Samuel C. Wadsworth, Dr. Chief Scientific Office 72 2017
Thomas Richard Kassberg Chief Business Officer & Executive Vice President 60 2016
Vimal Srivastava Senior VP-Development & Alliance Management 55 2018
John Richard Pinion Chief Quality Operations Officer 55 2017
Eric Crombez, Dr. Chief Medical Officer-Gene Therapy Development - 2017
Erik C. Harris Chief Commercial Officer & Executive VP 51 2019
Karah Parschauer Chief Legal Officer & Executive Vice President 44 -
Members of the board
Name Title Age Since
Daniel Welch Non-Executive Chairman 63 2015
Matthew K. Fust Independent Director 56 2014
Michael A. Narachi Independent Director 61 2015
Lars G. Ekman, Dr. Independent Director 71 2016
Deborah Dunsire Independent Director 59 2017
Shehnaaz Suliman, Dr. Independent Director 49 2019
Corazon Dating Sanders, Dr. Independent Director 64 2021
Amrit Ray, Dr. Independent Director 48 2022
Emil Kakkis President, Chief Executive Officer & Director 60 2010
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 70,105,654 66,653,402 95.1% 0 0.0% 95.1%
Shareholders
NameEquities%
T. Rowe Price Associates, Inc. (Investment Management) 10,780,156 15.4%
The Vanguard Group, Inc. 6,039,776 8.62%
Wellington Management Co. LLP 4,414,440 6.30%
Federated Global Investment Management Corp. 3,792,300 5.41%
Capital Research & Management Co. (International Investors) 3,412,406 4.87%
Emil Kakkis 2,843,967 4.06%
ClearBridge Investments LLC 2,837,143 4.05%
SSgA Funds Management, Inc. 2,457,308 3.51%
BlackRock Fund Advisors 1,649,209 2.35%
Avidity Partners Management LP 1,479,500 2.11%
Holdings
NameEquities%Valuation
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) 1,200,000 4.52% 21,240,000 USD
SOLID BIOSCIENCES INC. (SLDB) 521,722 6.93% 3,344,238 USD
Company contact information
Ultragenyx Pharmaceutical, Inc.
60 Leveroni Court
Novato, CA 94949

Phone : +1.415.483.8800
Fax : +1.415.483.8810
Web : http://www.ultragenyx.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Ultragenyx Pharmaceutical Inc.